Nosek Krzysztof, Leppert Wojciech, Nosek Hanna, Wordliczek Jerzy, Onichimowski Dariusz
Non-public Saint Lazarius Health Care Unit, Biskupiec.
Chair and Department of Palliative Medicine, Poznan University of Medical Sciences, Poznań.
Drug Des Devel Ther. 2017 Aug 22;11:2409-2419. doi: 10.2147/DDDT.S141007. eCollection 2017.
To compare analgesia and adverse effects during oral morphine and oxycodone and transdermal fentanyl and buprenorphine administration in cancer patients with pain.
Cancer patients treated at home and in outpatient clinics with severe pain (numerical rating scale score 6-10) fail to respond to non-opioids and/or weak opioids. All patients were randomized to either morphine, oxycodone, fentanyl or buprenorphine and divided into subgroups with predominant neuropathic and nociceptive pain component. Doses of opioids were titrated to satisfactory analgesia and acceptable adverse effects intensity. Patients were assessed at baseline and followed for 28 days. In all patient groups, immediate-release oral morphine was the rescue analgesic and lactulose 10 mL twice daily was the prophylaxis of constipation; no antiemetics were used as prophylaxis.
A total of 62 patients participated and 53 patients completed the study. Good analgesia was obtained for all 4 opioids, for both nociceptive and neuropathic pain. The use of co-analgesics was greater in patients with neuropathic pain. Morphine treatment was associated with less negative impact of pain on ability to walk, work and activity (trend) according to Brief Pain Inventory-Short Form scores and less consumption of rescue morphine. The most common adverse effects included nausea and drowsiness, which increased at the beginning of the treatment and gradually decreased over the days to come. Appetite, well-being, anxiety, depression, and fatigue improved. There was no constipation (the Bowel Function Index scores were within normal range) during the treatment with all opioids. No changes were seen for constipation, vomiting and dyspnea.
All opioids were effective and well-tolerated. Morphine was the most effective in the improvement in some of the Brief Pain Inventory-Short Form items regarding negative impact of pain on patients' daily activities. Prophylaxis of constipation was effective; antiemetics may be considered for nausea prevention.
比较口服吗啡和羟考酮以及经皮给予芬太尼和丁丙诺啡对癌症疼痛患者的镇痛效果及不良反应。
在家中和门诊接受治疗的癌症患者,有严重疼痛(数字评分量表评分6 - 10),对非阿片类药物和/或弱阿片类药物无反应。所有患者随机分为接受吗啡、羟考酮、芬太尼或丁丙诺啡治疗组,并根据主要的神经病理性疼痛和伤害性疼痛成分分为亚组。阿片类药物剂量滴定至满意镇痛效果且不良反应强度可接受。患者在基线时进行评估,并随访28天。在所有患者组中,即释口服吗啡为解救镇痛药,每日两次服用10 mL乳果糖预防便秘;未使用止吐药进行预防。
共有62例患者参与,53例患者完成研究。所有4种阿片类药物对伤害性疼痛和神经病理性疼痛均有良好的镇痛效果。神经病理性疼痛患者使用辅助镇痛药更多。根据简明疼痛问卷简表评分,吗啡治疗对疼痛对行走、工作和活动能力的负面影响较小(有趋势),且解救吗啡消耗量较少。最常见的不良反应包括恶心和嗜睡,在治疗开始时增加,随后几天逐渐减少。食欲、幸福感、焦虑、抑郁和疲劳均有改善。所有阿片类药物治疗期间均无便秘(肠道功能指数评分在正常范围内)。便秘、呕吐和呼吸困难未见变化。
所有阿片类药物均有效且耐受性良好。吗啡在改善简明疼痛问卷简表中一些关于疼痛对患者日常活动负面影响的项目方面最有效。便秘预防有效;可考虑使用止吐药预防恶心。